Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Syndax Announces Participation at Three Upcoming Investor Conferences

Syndax
Posted on: 29 Aug 18

WALTHAM, Mass., Aug. 28, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq : SNDX ), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of the management team will participate in three upcoming investor conferences. The details for the three conferences are:

B. Riley FBR Healthcare Conference at the New York Marriott East Side on Tuesday, September 4, 2018. Panel discussion at 11:20 a.m. ET.

Citi's 13th Annual Biotech Conference at the Four Seasons Hotel Boston on Wednesday, September 5, 2018.

Morgan Stanley 16th Annual Global Healthcare Conference at the Grand Hyatt Hotel New York on Friday, September 14, 2018. Fireside chat at 12:15 p.m. ET.

A live webcast of the Morgan Stanley 16th Annual Global Healthcare Conference fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the events will also be available for a limited time.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company is developing its lead product candidate, entinostat, a once-weekly, oral, small molecule, class I HDAC inhibitor, in combination with exemestane and several approved PD-1/PD-L1 antagonists. The Company's pipeline also includes SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, as well as a portfolio of potent and selective inhibitors targeting the binding interaction of Menin with MLLr. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.

Syndax Contacts

Investor Contact

Melissa Forst

Argot Partners

melissa@argotpartners.com

Tel 212.600.1902

Media Contact

David Rosen

Argot Partners

david.rosen@argotpartners.com

Tel 212.600.1902

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 29/08/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.